Pharmacokinetics of recombinant interferon alpha-C
| Autor: | Dina G. Fischer, Ofer Merimsky, Menachem Rubinstein, Abraham Danon, Samario Chaitchik |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment Cmax Alpha (ethology) Toxicology Injections Intramuscular Pharmacokinetics Interferon Internal medicine medicine Humans Pharmacology (medical) Neoplasm Metastasis Carcinoma Renal Cell Aged Pharmacology business.industry Middle Aged Kidney Neoplasms Recombinant Proteins Bioavailability Endocrinology Cytokine Oncology Interferon Type I Specific activity Female business Intramuscular injection medicine.drug Half-Life |
| Zdroj: | Cancer chemotherapy and pharmacology. 27(5) |
| ISSN: | 0344-5704 |
| Popis: | Recombinant interferon alpha-C (rIFN alpha-C, Interpharm), is a new type of alpha-interferon that has a specific activity of 1-2 x 10(9) units/mg protein. The pharmacokinetics of rIFN alpha-C were studied in 11 patients with metastatic renal-cell carcinoma. A total of 10 million units IFN alpha-C were injected intramuscularly and the serum level of IFN was evaluated up to 72 h post-administration. Measurable IFN concentrations appeared in the serum as early as 0.5 h, and levels peaked at 4-6 h (Cmax = 53.2 +/- 4.6 units/ml). Relatively high levels persisted for 24 h and declined thereafter with an apparent half-life of 3-4 h. The mean area under the serum-concentration curve (AUC) was 1,259 +/- 145 units h ml-1, indicating good bioavailability of the preparation from the intramuscular injection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink